{"id":382840,"date":"2020-11-17T08:04:15","date_gmt":"2020-11-17T13:04:15","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=382840"},"modified":"2020-11-17T08:04:15","modified_gmt":"2020-11-17T13:04:15","slug":"ayala-pharmaceuticals-reports-third-quarter-2020-financial-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ayala-pharmaceuticals-reports-third-quarter-2020-financial-results-and-provides-business-update\/","title":{"rendered":"Ayala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update"},"content":{"rendered":"
\n

\n – <\/em>
\n Presented <\/em>
\n N<\/em>
\n ew <\/em>
\n P<\/em>
\n ositive <\/em>
\n I<\/em>
\n nterim <\/em>
\n D<\/em>
\n ata from <\/em>
\n 4mg <\/em>
\n C<\/em>
\n ohort of <\/em>
\n Phase 2 ACCURACY <\/em>
\n S<\/em>
\n tudy of<\/em>
\n AL101 for the <\/em>
\n T<\/em>
\n reatment of R\/M ACC<\/em>
\n at <\/em>
\n European Society <\/em>
\n for Medical Oncology<\/em>
\n 2020<\/em>
\n –<\/em>
\n \n <\/p>\n

\n – <\/em>
\n Trial In Progress Poster of Phase 2 TENACITY Study of <\/em>
\n AL101 Monotherapy in Patients <\/em>
\n w<\/em>
\n ith<\/em>
\n Notch-activated Triple-Negative Breast Cance<\/em>
\n r Accepted for Presentation<\/em>
\n at San Antonio Breast Cancer<\/em>
\n Virtual<\/em>
\n Symposium <\/em>
\n –<\/em>\n <\/p>\n

REHOVOT, Israel\u00a0and WILMINGTON, Del., Nov. 17, 2020 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today reported financial results for the third quarter ended September 30, 2020 and highlighted recent progress and upcoming milestones for its pipeline programs.<\/p>\n

\u201cAyala has made important steps forward in just over a quarter since our IPO as we have laid a strong financial and clinical foundation to support several upcoming milestones throughout the remainder of 2020 and into 2021. Most importantly, we announced encouraging new interim data from our Phase 2 ACCURACY study of AL101 in an extremely difficult to treat population, R\/M ACC, demonstrating that AL101 4mg monotherapy has the potential to be a safe and effective treatment for patients with Notch activating mutations. These data further support our rationale for evaluating the 6mg dose cohort of this study for which we remain on track with enrollment,\u201d said Roni Mamluk, Ph.D., Chief Executive Officer of Ayala. \u201cOur broader pipeline focused on genetically defined cancers continues to advance and we look forward to commencing patient dosing of our Phase 2 TENACITY study of AL101 for the treatment of R\/M TNBC by year-end 2020, as well as additional trial initiations for desmoid tumors in the first half of 2021 and T-ALL in the second half of 2021.\u201d<\/p>\n

\n Key Business and Clinical Highlights <\/strong>\n <\/p>\n